BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Namida Lab, a global pioneering tear-based cancer screening, unveiled Auria®, the groundbreaking at-home biological breast cancer screening test, at the New Technology Showcase during the 32nd Annual Interdisciplinary Breast Center Conference (NCoBC) in Las Vegas.

X4 Pharmaceuticals, a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced that, effective on March 31, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Celyad Oncology received a letter on March 31, 2023 from The Nasdaq Stock Market informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450 for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10.0 million.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report first quarter 2023 financial results on Thursday, April 27, 2023, before the market opens.

Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2023 following the close of market on Tuesday, April 25, 2023.

Akebia Therapeutics, Inc. granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia’s common stock on March 31, 2023, as an inducement material to such employee entering into employment with Akebia.

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 39,300 shares of Astria’s common stock on April 3, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

Johnson & Johnson announced that its subsidiary LTL Management LLC has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will equitably and efficiently resolve all claims arising from cosmetic talc litigation against the Company and its affiliates in North America.

Dr. Hamid Abbasi, a renowned spine surgeon and innovator, has successfully performed the first Inspired Spine Trans-Kambin Oblique Lateral Lumbar Interbody Fusion with Arrow Cage in South America.